Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Halozyme Therapeutics clinical trials
The registry lists 42 studies whose lead sponsor is Halozyme Therapeutics or one of 1 company grouped under it. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 18, 2026.
Keep track of what changes. Save the Halozyme Therapeutics studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Halozyme Therapeutics.
- Halozyme Therapeutics33 studiesSame company
Something wrong?
- Antares Pharma Inc.9 studies →Acquired — became part of Halozyme Therapeutics, May 24, 2022 · source ↗
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 42 of 42.
- 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With HypogonadismRecruitingNCT06689085Phase 3
- Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact DermatitisCompletedNCT00928447Phase 2
- Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder CancerCompletedNCT00318643Phase 1/2
- PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic CancerCompletedNCT01839487Phase 2
- A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal AdenocarcinomaTerminatedNCT02715804Phase 3
- Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder AdenocarcinomaTerminatedNCT03267940Phase 1
- A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid TumorsCompletedNCT02563548Phase 1
- Pharmacokinetic Study of Subcutaneous Testosterone EnanthateCompletedNCT02233751Phase 1
Sponsor listed in the registry: Antares Pharma Inc. · First submitted before Antares Pharma Inc. became part of Halozyme Therapeutics
- Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20CompletedNCT00705536Phase 1
- Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes MellitusCompletedNCT00774800Phase 2
- Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human HyaluronidaseCompletedNCT01526733Phase 4
- Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes MellitusCompletedNCT01194245Phase 2
- A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLCTerminatedNCT02346370Phase 1
- A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)CompletedNCT03662334Phase 4
- Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic CancerCompletedNCT01453153Phase 1/2
- Subcutaneous Rehydration Compared to Intravenous RehydrationCompletedNCT00773175Phase 4
- CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)CompletedNCT01848990Phase 4
- Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)CompletedNCT00656370Phase 4
- Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20CompletedNCT00803972Phase 1
- Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate AloneCompletedNCT00807963Phase 1
- Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With HypogonadismCompletedNCT02504541Phase 3
Sponsor listed in the registry: Antares Pharma Inc. · First submitted before Antares Pharma Inc. became part of Halozyme Therapeutics
- Safety of Subcutaneous Testosterone Enanthate in Adult Male HypogonadismCompletedNCT02777242Phase 2
Sponsor listed in the registry: Antares Pharma Inc. · First submitted before Antares Pharma Inc. became part of Halozyme Therapeutics
- Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With HypogonadismCompletedNCT02159469Phase 3
Sponsor listed in the registry: Antares Pharma Inc. · First submitted before Antares Pharma Inc. became part of Halozyme Therapeutics
- Pharmacokinetic Study of Testosterone EnanthateCompletedNCT01887418Phase 1/2
Sponsor listed in the registry: Antares Pharma Inc. · First submitted before Antares Pharma Inc. became part of Halozyme Therapeutics
- Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes MellitusCompletedNCT00883558Phase 2
- Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes MellitusCompletedNCT01194258Phase 2
- Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)CompletedNCT00916357Phase 2
- Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)CompletedNCT01275131Phase 1
- Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro AloneCompletedNCT00862849Phase 1
- A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs AloneCompletedNCT00979875Phase 1
- Study of Topically Administered Oxybutynin Gel in Patients With Urge IncontinenceCompletedNCT00909181Phase 3
Sponsor listed in the registry: Antares Pharma Inc. · First submitted before Antares Pharma Inc. became part of Halozyme Therapeutics
- Comparison of Methotrexate (MTX) and the VIBEX™ MTX DeviceCompletedNCT01618968Phase 2
Sponsor listed in the registry: Antares Pharma Inc. · First submitted before Antares Pharma Inc. became part of Halozyme Therapeutics
- Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector DeviceCompletedNCT01618955Phase 2
Sponsor listed in the registry: Antares Pharma Inc. · First submitted before Antares Pharma Inc. became part of Halozyme Therapeutics
- Exposure Study Comparing 3 Routes of Methotrexate (MTX) AdministrationCompletedNCT01737944Phase 1/2
Sponsor listed in the registry: Antares Pharma Inc. · First submitted before Antares Pharma Inc. became part of Halozyme Therapeutics
- Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid TumorsCompletedNCT01170897Phase 1
- Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy VolunteersCompletedNCT01572012Phase 1
- Safety Study of PEGPH20 Given to Patients With Advanced Solid TumorsCompletedNCT00834704Phase 1
- A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human HyaluronidaseCompletedNCT00435604Phase 1
- Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder CancerCompletedNCT00782587Phase 1
- INFUSE Morphine StudyCompletedNCT00593281Phase 3
- Study of a Large Protein Molecule Administered With Escalating Doses of Recombinant Human HyaluronidaseCompletedNCT00369187Phase 4
- A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer SubjectsCompletedNCT00311519Phase 4